The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 

Simultaneous analysis of the serum and urinary pharmacokinetics of fortimicin A after intravenous administration to healthy subjects.

The present study was conducted to evaluate the single-dose pharmacokinetics of the pseudodisaccharide antibiotic, fortimicin A, in humans, following intravenous infusion of 2.5, 5.0, and 7.5 mg per kg doses of the free base (as fortimicin A sulfate) to 17 volunteers who were randomly assigned to each of three dose groups containing six, six, and five subjects, respectively. Each dose was infused in 100 ml of 5% glucose/water over 57-63 min (i.e., an infusion rate of approximately 1.7 ml per min). Serum samples were obtained at 0, 1, 1.25, 1.5, 1.75, 2, 3, 5, 6, 8, and 12 h after the start of the infusion. Urine was collected in 0-4, 4-8, 8-12, and 12-24 h fractions (also relative to start of infusion). Determinations of fortimicin A concentrations were performed microbiologically on urine samples, and with a unique immunologic procedure on serum samples. Serum concentration-time and cumulative urinary excretion-time data for each subject were simultaneously fit to a two-compartment open model with zero-order absorption (i.e., infusion) and biexponential elimination. Of the six pharmacokinetic parameters studied (K21, K12, KNet, V1, cumulative fraction of drug excreted to infinite time, and renal clearance), significant (p = 0.05) dose-related differences were found only in the mean renal clearances between the 2.5 mg/kg dose group and the other two; however, this was of questionable practical importance. The overall mean beta-phase half-live was about 1.8 h, with little subject-to-subject variability.[1]

References

  1. Simultaneous analysis of the serum and urinary pharmacokinetics of fortimicin A after intravenous administration to healthy subjects. Sennello, L.T., Berman, B.I., Vance, J.F., Sonders, R.C. International journal of clinical pharmacology, therapy, and toxicology. (1982) [Pubmed]
 
WikiGenes - Universities